Skip to main content

Table 2 Baseline diagnostics and demographic characteristics

From: Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Age (years), median (IQR)

64.3 (52.1-73.5)

Follow-up time monthsa, median (IQR)

18.4 (10.5-26.1)

Gender

 Male

3165/5307 (59.6%)

 Female

2142/5307 (40.4%)

ECOG performance status

 0

2374/3925 (60.5%)

 1

1110/3925 (28.3%)

 2

279/3925 (7.1%)

 3

119/3925 (3.0%)

 4

43/3925 (1.1%)

Diagnosis

 Diffuse large B cell lymphoma (DLBCL)

1717/5314 (32.3%)

 Follicular lymphoma

816/5314 (15.4%)

 Other B cell non-Hodgkin lymphoma

909/5314 (17.1%)

 Hodgkin Lymphoma

751/5314 (14.1%)

 Chronic lymphocytic leukaemia (CLL)

560/5314 (10.5%)

 T-cell non-Hodgkin lymphoma

283/5314 (5.3%)

 Mantle cell lymphoma

249/5314 (4.7%)

 Post-transplant lymphoproliferative disease

29/5314 (0.5%)

  1. aFor prospectively identified patients only